FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
This office will be the central hub for all operations related to companies ethical pharmaceutical business
This approval reflects company’s unwavering commitment that the quality assurance
Subscribe To Our Newsletter & Stay Updated